Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Meille

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Cancer Chemotherapy and Pharmacology|February 23, 2015
Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibodyGeorgina Meneses-Lorente, Thomas Friess, Irene Kolm, et al.
Cancer Research|June 16, 2016
Mathematical Modeling of Cancer Immunotherapy and Its Synergy with RadiotherapyRaphael Serre, Sebastien Benzekry, Laetitia Padovani, et al.
Cancer Research|June 29, 2017
Pharmacokinetics and Pharmacodynamics-Based Mathematical Modeling Identifies an Optimal Protocol for Metronomic ChemotherapyJoseph Ciccolini, Dominique Barbolosi, Christophe Meille, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 25, 2021
A framework to guide dose & regimen strategy for clinical drug developmentOliver Sander, Baldur Magnusson, Inga Ludwig, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 31, 2015
Model-based assessment of erlotinib effect in vitro measured by real-time cell analysisStephan Benay, Christophe Meille, Stefan Kustermann, et al.
Oncotarget|April 9, 2017
Modeling therapeutic response to radioiodine in metastatic thyroid cancer: a proof-of-concept study for individualized medicineDominique Barbolosi, Ilyssa Summer, Christophe Meille, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2014
Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approachBrian Higgins, Kelli Glenn, Antje Walz, et al.
The AAPS Journal|January 5, 2017
Metabolic Profiling of Human Long-Term Liver Models and Hepatic Clearance Predictions from In Vitro Data Using Nonlinear Mixed-Effects ModelingNicole A Kratochwil, Christophe Meille, Stephen Fowler, et al.
British Journal of Cancer|June 18, 2021
Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studiesSebastian Bauer, George D Demetri, Ensar Halilovic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2021
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute LeukemiaEytan M Stein, Daniel J DeAngelo, Jörg Chromik, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Cancer Chemotherapy and Pharmacology|February 23, 2015
Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibodyGeorgina Meneses-Lorente, Thomas Friess, Irene Kolm, et al.
Cancer Research|June 16, 2016
Mathematical Modeling of Cancer Immunotherapy and Its Synergy with RadiotherapyRaphael Serre, Sebastien Benzekry, Laetitia Padovani, et al.
Cancer Research|June 29, 2017
Pharmacokinetics and Pharmacodynamics-Based Mathematical Modeling Identifies an Optimal Protocol for Metronomic ChemotherapyJoseph Ciccolini, Dominique Barbolosi, Christophe Meille, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 25, 2021
A framework to guide dose & regimen strategy for clinical drug developmentOliver Sander, Baldur Magnusson, Inga Ludwig, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 31, 2015
Model-based assessment of erlotinib effect in vitro measured by real-time cell analysisStephan Benay, Christophe Meille, Stefan Kustermann, et al.
Oncotarget|April 9, 2017
Modeling therapeutic response to radioiodine in metastatic thyroid cancer: a proof-of-concept study for individualized medicineDominique Barbolosi, Ilyssa Summer, Christophe Meille, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2014
Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approachBrian Higgins, Kelli Glenn, Antje Walz, et al.
The AAPS Journal|January 5, 2017
Metabolic Profiling of Human Long-Term Liver Models and Hepatic Clearance Predictions from In Vitro Data Using Nonlinear Mixed-Effects ModelingNicole A Kratochwil, Christophe Meille, Stephen Fowler, et al.
British Journal of Cancer|June 18, 2021
Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studiesSebastian Bauer, George D Demetri, Ensar Halilovic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2021
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute LeukemiaEytan M Stein, Daniel J DeAngelo, Jörg Chromik, et al.
Pageof 3